Graves’ Ophthalmopathy Market to Register Stunning Growth During the Forecast Period (2022-2032) – DelveInsight | Key Companies – Novartis, Harbour BioMed, Immunovant, Viridian, Sling Therapeutics
Major pharma and biotech giants such as Immunovant Sciences, Novartis Pharmaceuticals, Viridian Therapeutics, Sling Therapeutics, Regeneron Pharmaceuticals, ValenzaBio, and several others are evaluating their lead candidates in different stages of clinical development. There are several promising drugs in the pipeline, including VRDN-001 (Viridian Therapeutics) and IMVT-1401 (Immunovant Sciences GmbH), among others, expected to hit the market in the near future.
DelveInsight’s “Graves’ Ophthalmopathy Market Insights, Epidemiology, and Market Forecast 2032” report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the Graves’ Ophthalmopathy market size, share, trends, and growth opportunities in the seven major markets (7MM) (i.e., the United States, EU4 (Germany, Spain, Italy, France), the United Kingdom and Japan).
The Graves’ Ophthalmopathy market report covers emerging drugs, current treatment practices, market share of individual therapies, and current & forecasted market size from 2019 to 2032. It also evaluates the current treatment practice/algorithm, key drivers & barriers impacting the market growth, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.
Graves’ Ophthalmopathy: An Overview
Graves’ ophthalmopathy is a complex orbital inflammatory disease that can be sight-threatening, debilitating, and disfiguring. Graves’ ophthalmopathy, also known as thyroid eye disease (TED), is named after Robert J. Graves, an Irish physician who first described thyrotoxicosis in a woman presenting with goitre, rapid heartbeat, and exophthalmos.
Graves’ ophthalmopathy affects eye muscles, eyelids, tear glands, and fatty tissues behind the eye to become inflamed. This can cause the eyes and eyelids to become red, swollen, and uncomfortable, and the eyes can be pushed forward (‘staring’ or ‘bulging’ eyes). Untreated thyroid dysfunction (hyper- or hypothyroidism) is associated with the development and progression of Graves’ ophthalmopathy. Smoking is the strongest risk factor associated with Graves’ ophthalmopathy.
According to NORD, the exact prevalence (i.e., the number of people who have a disorder in a specific population at a specific time) of Graves’ ophthalmopathy is not known but is estimated to be 16 per 100,000 women in the general population, and 2.9 per 100,000 men in the general population.
Graves’ Ophthalmopathy Market Key Facts
The total market size of Graves’ Ophthalmopathy in the 7MM was approximately USD 1,993 million in 2022 and is projected to increase during the forecast period (2023–2032).
The market size in the 7MM will increase due to recent efforts to increase patient and clinician awareness of Graves Ophthalmopathy, with various awareness campaigns, are expected to increase early diagnosis and treatment of Graves Ophthalmopathy.
Among EU4 countries, Germany accounted for the maximum market size in 2022.
By 2032, among all the emerging therapies, the highest revenue is expected to be generated by batoclimab, followed by Vrdn-001 and secukinumab in the 7MM.
The total prevalent cases of Graves Ophthalmopathy in the United States were around 1,012,000 cases in 2022.
The US contributed to the largest prevalent population of Graves’ Ophthalmopathy, acquiring ~42% of the 7MM in 2022. Whereas Germany accounted for around 13% and Japan accounted for around 8% of the total population share, respectively, in 2022.
Among EU4 countries, Germany accounted for the largest number of Graves’ Ophthalmopathy cases, followed by France, whereas Spain accounted for the lowest number of cases in 2022.
According to DelveInsight estimates, there were around 16,300 cases of acute Graves’ Ophthalmopathy and 41,900 cases of chronic Graves’ Ophthalmopathy in Japan in 2022. These cases are projected to increase during the forecasted period.
In the 7MM, approximately 20% of the patient share is attributed to males, whereas only 80% of females suffer from Graves’ Ophthalmopathy.
The diagnosis and treatment rate of Graves’ Ophthalmopathy is expected to increase in the coming years due to the increase in expected approvals of several pipeline candidates for the treatment of Graves’ Ophthalmopathy, thus leading to the increase in awareness among patients and clinicians.
The market outlook section of the report helps to build a detailed comprehension of the historical, current and forecasted Graves’ Ophthalmopathy market size by analyzing the impact of current and emerging pipeline therapies. It also thoroughly assesses the market drivers & barriers, unmet needs, and emerging technologies set to impact the market dynamics.
The report gives complete detail of the Graves’ Ophthalmopathy market trend for each marketed drug and mid & late-stage pipeline therapies by evaluating their impact based on the annual cost of therapy, their Mechanism of Action (MOA), Route of Administration (ROA), molecule types, competition with other therapies, brand value, and their impact on the market.
Graves’ Ophthalmopathy Epidemiology Assessment
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2019 to 2032. It helps to recognize the causes of current and forecasted epidemiology trends by exploring numerous studies and research. The epidemiology section also provides a detailed analysis of diagnosed and prevalent patient pool, future trends, and views of key opinion leaders.
The Report Covers the Graves’ Ophthalmopathy Epidemiology, Segmented as –
Total Prevalent cases of Graves’ ophthalmopathy in 7MM [2019–2032
Gender-specific cases of Graves’ ophthalmopathy in 7MM [2019–2032]
Severity-Specific Cases of Graves’ ophthalmopathy in 7MM [2019–2032]
Age-specific cases of Graves’ ophthalmopathy in 7MM [2019–2032]
Graves’ Ophthalmopathy Drugs Uptake and Pipeline Development Activities
The drug uptake section focuses on the uptake rate of potential drugs recently launched in the Graves’ Ophthalmopathy market or expected to be launched during the study period. The analysis covers the Graves’ Ophthalmopathy market uptake by drugs, patient uptake by therapies, and sales of each drug. Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Graves’ Ophthalmopathy pipeline development activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyses recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Learn How the Graves’ Ophthalmopathy Market Will Evolve and Grow by 2032 @
Graves’ Ophthalmopathy Therapeutics Analysis
Several major pharma and biotech giants are developing therapies for Graves Ophthalmopathy. Currently, Novartis is leading the therapeutics market with its Graves Ophthalmopathy drug candidates in the most advanced stage of clinical development.
Leading Companies in the Graves Ophthalmopathy Therapeutics Market Include:
Viridian Therapeutics, Inc.
Suzhou Suncadia Biopharmaceuticals Co., Ltd.
Sling Therapeutics, Inc.
And Many Others
Graves Ophthalmopathy Therapies Covered in the Report Include:
Tepezza (teprotumumab) : Horizon Therapeutics
Batoclimab (HBM9161): Harbour BioMed
TEPEZZA (teprotumumab): Horizon Therapeutics
Batoclimab: Immunovant Sciences
VRDN-001: Viridian Therapeutics
Linsitinib : Sling Therapeutics
And Many More
The Report Covers the In-depth Assessment of the Emerging Drugs & Key Companies. Download the Sample Report to Learn More @
Table of Content (TOC)
1. Key Insights
2. Executive Summary
3. Graves’ Ophthalmopathy Competitive Intelligence Analysis
4. Graves’ Ophthalmopathy Market Overview at a Glance
5. Graves’ Ophthalmopathy Disease Background and Overview
6. Graves’ Ophthalmopathy Patient Journey
7. Graves’ Ophthalmopathy Epidemiology and Patient Population (In the US, EU5, and Japan)
8. Graves’ Ophthalmopathy Treatment Algorithm, Current Treatment, and Medical Practices
9. Graves’ Ophthalmopathy Unmet Needs
10. Key Endpoints of Graves’ Ophthalmopathy Treatment
11. Graves’ Ophthalmopathy Marketed Products
12. Graves’ Ophthalmopathy Emerging Drugs and Latest Therapeutic Advances
13. Graves’ Ophthalmopathy Seven Major Market Analysis
14. Attribute Analysis
15. Graves’ Ophthalmopathy Market Outlook (In US, EU5, and Japan)
16. Graves’ Ophthalmopathy Access and Reimbursement Overview
17. KOL Views on the Graves’ Ophthalmopathy Market
18. Graves’ Ophthalmopathy Market Drivers
19. Graves’ Ophthalmopathy Market Barriers
21. DelveInsight Capabilities
*The Table of Contents (TOC) is not exhaustive; the final content may vary. Refer to the sample report for the complete table of contents.
Download the Sample PDF to Learn More About the Key Offerings of the Report @
Connect with us and discover how Delveinsight can help you to identify your potential business partners and investors in the highly dynamic and evolving healthcare market today @ Healthcare Partner Identification Services
DelveInsight is a leading Business Consultant and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Address:304 S. Jones Blvd #2432
City: Las Vegas
Country: United States